Revolutionary weight-loss jab Tirzepatide - which is sold under the name Zepbound - could save patients from life-threatening liver failure, study finds By Meike Leonard Published: 00:33, 9 June 2024 | Updated: 01:02, 9 June 2024 e-mail View comments A revolutionary weight-loss jab could save patients from life-threatening liver failure, a study has discovered. Tirzepatide, sold under the name Zepbound, is an injectable anti-obesity drug that suppresses appetite by artificially activating the hormones that make you feel full – much like popular jabs Ozempic and Wegovy. Yet fresh research suggests patients on tirzepatide – which was last week approved for use on the NHS – lose twice as much weight compared to those taking Ozempic or Wegovy.

But the weekly jab could also transform liver disease treatment, the study reveals. More than half of patients with fatty liver disease, often triggered by obesity, saw an improvement in their symptoms after being given tirzepatide. Tirzepatide (pcitured), sold under the name Zepbound, is an injectable anti-obesity drug that suppresses appetite by artificially activating the hormones that make you feel full More than half of patients with fatty liver disease, often triggered by obesity, saw an improvement in their symptoms after being given tirzepatide (Stock image) The condition occurs when excess fat cells inflame the liver and cause scarring – known as fibrosis.

Some 10,000 people in the UK die every year due to liver disease onc.